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Neurodegenerative diseases selectively target subpopulations of neurons, leading to the progressive failure
of definedbrain systems, but the basis of such selective neuronal vulnerability has remained elusive. Here, we
discuss how a stressor-threshold model of how particular neurons and circuits are selectively vulnerable to
diseasemay underly the etiology of familial and sporadic forms of diseases such as Alzheimer’s, Parkinson’s,
Huntington’s, and ALS. According to this model, the intrinsic vulnerabilities of neuronal subpopulations to
stressors and specific disease-relatedmisfolding proteins determine neuronalmorbidity. Neurodegenerative
diseases then involve specific combinations of genetic predispositions and environmental stressors, trig-
gering increasing age-related stress and proteostasis dysfunction in affected vulnerable neurons. Damage
to vasculature, immune system, and local glial cells mediates environmental stress, which could drive
disease at all stages.Introduction
Neurodegenerative diseases (NDDs) such as Alzheimer’s
disease (AD), Parkinson’s disease (PD), Huntington’s disease
(HD), and amyotropic lateral sclerosis (ALS) each primarily affect
defined subsets of neurons and involve characteristic ranges of
pathological and molecular features. The main risk factor for
NDDs is advancing age.
The accumulation of distinct protein-based macroscopic
deposits is a hallmark of NDDs. Although phenotypic variations
and comorbidities are frequent, the composition and distribution
of the deposits is a defining property of each NDD, and some of
themutations associatedwith familial cases of the diseases affect
folding of the major protein components of the deposits. Accord-
ingly, NDDs are currently viewed as cerebral proteopathies, in
which the accumulation of particular misfolded proteins is a key
causative factor (e.g., Haass and Selkoe, 2007; Golde and Miller,
2009; Frost and Diamond, 2010). Since the misfolding proteins
implicated in the etiology of NDDs are expressed ubiquitously, a
majorunresolvedquestion ishowdeposit formationandpathology
neverthelessselectively targetspecificsubpopulationsofneurons.
In addition to specific misfolding proteins, NDDs exhibit
comparable patterns of proteostasis, signaling pathway, and
organelle dysfunction (Wallace, 2005; Lin and Beal, 2006; Knott
et al., 2008; Morimoto, 2008; Matus et al., 2011) and consistently
involve pathways that regulate energy metabolism and cell
repair, which have been implicated in the control of life span
and aging (Hsu et al., 2003; Cui et al., 2006; Cohen and Dillin,
2008; Gan and Mucke, 2008; Cohen et al., 2009). Accordingly,
selective neuronal vulnerability may involve neuron specific
combinations of dysfunctions in cellular stress and proteostasis
pathways, aggravated by advancing age.
This review focuses on the roles of specific neuronal vulnerabil-
ities in theetiologyofNDDs, i.e., onhow intrinsicandenvironment-induced cellular stress and homeostasis pathways may intersect
with the accumulation of misfolding proteins in particular vulner-
able neurons to promote disease. More detailed treatments of
each NDD, and of the key roles of local microenvironment factors
such as glial dysfunction, immune system engagement, and
vascular dysfunction in disease can be found in recent reviews
(e.g., Zlokovic, 2005; Boille´e et al., 2006b; Maragakis and Roth-
stein, 2006; Ballatore et al., 2007; Cepeda et al., 2007; Hawkes
et al., 2007; Balch et al., 2008; Zacchigna et al., 2008; Golde and
Miller, 2009; Ron-Harel and Schwartz, 2009; Glass et al., 2010).
A Stressor-Threshold Model of Selective Neuronal
Vulnerability
As will be discussed below, a survey of disease mechanisms in
AD, PD, HD, and ALS suggests that the neurons selectively
vulnerable to NDDs are particularly sensitive to particular
stressors, and subject to high physiological levels of excitation
and intracellular Ca loads (e.g., Lin and Beal, 2006; Palop
et al., 2006; Gleichmann and Mattson, 2010; Prahlad and Mori-
moto, 2009). Further sources of intrinsic stressor load relevant
to disease include genetic background, preexisting conditions
(e.g., diabetes), and advancing age. In addition to such predis-
posing factors, disease-relevant environmental stressors can
include chronic consequences of physical and ischemic lesions
(Vermeer et al., 2003; Blasko et al., 2004; Szczygielski et al.,
2005), lesions left behind by previous infections, and chronic
consequences of stress and environmental toxins. For example,
repeated head trauma in football players is highly correlated with
subsequent tauopathy with dementia (McKee et al., 2009).
Based on these considerations, we discuss a stressor-load
model to account for how specific neuronal subpopulations
contribute to the etiology of NDDs and how familial and
sporadic forms of the diseases produce comparable diseaseNeuron 71, July 14, 2011 ª2011 Elsevier Inc. 35
Figure 1. Schematic of How Gradually Increasing Stress in Affected and Selectively Vulnerable Neurons May Underlie the Etiology and
Progression of NDDs
Specific NDDs may be defined by successive restrictions in the range of neurons affected by individual predispositions, local environmental factors, stress
susceptibility, and sensitivity to misfolding-prone proteins. The connectivity and excitability properties of neuronal subpopulations may have a major role in
determining their intrinsic sensitivity to stress. Intrinsic distinctions in the susceptibility of neurons to individual misfolding-prone proteins may account for similar
disease patterns and pathology in sporadic and familial cases of the NDDs. Cascades of mutually reinforcing stress and proteostasis imbalance responses may
escalate in an age-sensitive manner in affected, stress-sensitive, and misfolding-protein-sensitive neurons, causing their dysfunction and death. The accu-
mulation of the toxic protein species may subsequently spread to other less vulnerable cells and increase their stressor load as well. Environmental factors may
affect several brain systems through systemic involvement, e.g., involving the vasculature, inflammatory responses and the immune system, as well as spreading
of toxic protein species.
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against a background of environmental injuries related to indi-
vidual ontogeny and genetic background, intrinsic stressors in
vulnerable neurons and those associated with specific cellular
protein, energy, and organelle homeostasis processes combine
toproduce vicious cyclesof increasing stressor loadandmisfold-
ing protein accumulation, eventually causing age-retaled degen-
eration in selectively vulnerable neurons (Figure 1). A tenet of the
proposal is that particular misfolding-prone proteins may accu-
mulate upon cell stress in or near the vulnerable neurons (first
vulnerability), to then selectively interfere with neuronal function
and causemore neuronal stress due to vulnerability tomisfolding
protein targets in those neurons (second vulnerability). The pres-
ence of such specific vulnerability combinations in particular
neurons would thus favor proteostasis instability through vicious
cycles involving cell stress and misfolding protein targets. In36 Neuron 71, July 14, 2011 ª2011 Elsevier Inc.suggesting that stressor levels have a critical role throughout
disease, the model differs from views that alterations in cellular
stress pathways in neurons are just late consequences of
disease.
The model implies the following:
 NDDs may be initiated by chronic perturbations acting at
any of several critical components of cellular homeostasis
pathways in vulnerable cells.
 Multiple stressors may converge and reinforce each other
in vicious cycles to drive dysfunction and eventually degen-
eration in vulnerable neurons and their local microenviron-
ment.
 Chronic disturbances that may lead to a NDD could initiate
at any age, producing gradually increasing neuronal dys-
function, but suprathreshold dysfunction and progressive
Neuron
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stressor tolerance fails to match the current load of
disease-related stressors.
 Systemic involvement may initiate and aggravate disease,
e.g., through vascular lesions, inflammation, and compro-
mised immune responses.
 Above suprathreshold stressor levels, disease-related
processes may include growing resident and systemic
immune system recruitment, neuronal degeneration and
death, and spreading of the pathology to less affected
parts of the nervous system.
We first provide a general overview of cellular stress and
homeostasis regulatory pathways and then reviewmain features
of NDDs and how they may be accounted for by a stressor-
threshold model of selective neuronal vulnerabilities.Cellular Stress and Homeostasis Pathways
All cells are endowed with homeostatic regulatory mechanisms
to cope with altered physiological demands, survive periods of
intense stress, adapt to milder but chronic stress, or self-
destroy. Cells can experience different types of stress, including
protein misfolding, high biosynthetic or secretory demands,
alterations in redox balance (e.g., oxydative stress), alterations
in organellar calcium, inflammatory reactions, caloric restriction,
and aging (Mattson and Magnus, 2006; Lin et al., 2008; Hotami-
sligil, 2010; Rutkowski and Hegde, 2010; Roth and Balch, 2011).
The cellular homeostasis processes that respond to cell stress
include combinations of specific pathways that deal with partic-
ular stressors (Rutkowski and Hegde, 2010; Roth and Balch,
2011). Not surprisingly, these pathways are highly intercon-
nected, leading to extensive crosstalk and comorbidities among
them. Notably, however, in spite of the great variety of specific
cellular homeostasis responses, the stress sensors associated
with the endoplasmic reticulum (ER) membrane system seem
to have central roles in orchestrating cell adaptions to altered
physiological demands and in response to stressors (Bernales
et al., 2006; Lin et al., 2008; Rutkowski and Hegde, 2010).
Such uniquely central roles likely relate to the fact that the ER
has major biosynthetic and secretory roles, is distributed
throughout the internal volume of cells, and exhibits specialized
interfaces with other membrane organelles such as the nucleus,
mitochondria, the Golgi apparatus, lysosomes, phagosomes,
and the plasma membrane, where stress signals can be
exchanged. In keeping with the fact that the accumulation of
misfolded proteins within its lumen is a major source of stress
to the ER, triggering of the full spectrum of stress responses
by the ER is designated the unfolded protein response (UPR).
From yeast tomammalian cells, the ERdeals with the accumu-
lation of misfolding proteins inside its lumen by the activation of
transmembrane ER stress sensors (Bernales et al., 2006; Ron
and Walter, 2007). In mammalian cells, these are IRE1, PERK,
and ATF6. IRE1 is the most conserved among the ER sensor
pathways. Upon activation, IRE1 exhibits kinase and endoribo-
nuclease activity, which leads to the nonconventional cytosolic
splicing of Xbp-1 mRNA, disinhibiting translation of the corre-
sponding transcription factor, which in turn promotes the
expression of UPR genes. In addition, IRE1 activation leads toactivation of the JNK and NFkB pathways. IRE1 is activated
upon stress signals from the ER lumen, but also by signals not
directly related to ER stress, including BAX, BAK, and ASK1-
interacting protein 1. Upon activation, PERK directly phosphory-
lates its main substrate eIF2a (a translation factor), leading to its
inactivation, inhibition of most translation, and enhanced trans-
lation of a few selected transcripts including ATF-4. The latter
then activates transcription of UPR genes. These include the
proapoptotic transcription factor CHOP (a.k.a. GADD153) and
the major ER chaperon BiP. PERK further activates Nrf2, which
acts against oxydative stress, and NFkB. Finally, activation of
ATF6 leads to its translocation from the ER to the Golgi, where
it is cleaved to produce a fragment that translocates to the
nucleus and promotes the transcription of UPR genes. In addi-
tion, ATF6 also activates the NFkB pathway. At first approxima-
tion, the activation of ER stress sensors thus leads to reduced
protein synthesis, and to the transcription of UPR genes. In
addition, ER stress sensors activate autophagy and inflamma-
tory responses (Hotamisligil, 2010; Kimata and Kohno, 2011).
Although ER chaperon proteins such as BiP, GRP94, Calnexin,
Calretinin, and PDI are certainly involved, the precise mecha-
nisms of how ER sensors are activated have remained poorly
understood (Kimata and Kohno, 2011). Several models include
a role for the relatively long-lived chaperons in preventing activa-
tion of the ER sensors by unfolded proteins. In addition to
reduced translation, and in order to prevent overt activation of
the UPR, the accumulation of misfolded proteins is counteracted
by ER-activated protein degradation (ERAD) processes. These
involve yet elusive channels to translocate misfolded proteins
from the ER lumen to the cytosol, where they are degraded via
polyuniquitination and the proteasome. To ensure homeostasis,
ERAD is modulated by regulators such as EDEM1 and ERManI,
proteins that are short lived in nonstressed cells.
Importantly, recruitment of ER stress pathways is not
restricted to stressed cells (Rutkowski and Hegde, 2010).
Thus, when cells initiate physiological processes that put higher
demands on homeostasis systems they activate ER stress path-
ways to pro-actively and specifically cope with those higher
demands. This is for example the case in differentiating B cells,
in cells preparing to fight infections upon Toll-like receptor
activation, in cells undergoing large morphologically changes
(including neurons), and in professional secretory cells such as
pancreatic b-cells. ER stress pathway recruitment in the base-
nce of extra stress has been firmly established in studies that
have used GFP reporters to visualize Xbp-1 activation and that
revealed physiological activation e.g., in liver or skeletal muscle
(Rutkowski and Hegde, 2010). There is thus extensive potential
for crosstalk and interference between cell homeostasis path-
ways upon stress or physiological conditions. Indeed, in addition
to protein misfolding, eIF2a phosphorylation is enhanced upon
hypoxia, changed nutritional status, hormonal activation, infec-
tion, or synaptic plasticity. Furthermore, ATF6 can interfere
with CREB mediated transcription due to recruitment of the
CREB coactivator CRTC2 upon ATF6 activation. Given that
physiological needs vary dramatically among different types of
cells, overlaps between stress and physiological responses at
ER stress pathways exhibit cell type specific features. The
mechanisms that ensure that specific physiological demandsNeuron 71, July 14, 2011 ª2011 Elsevier Inc. 37
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activation of ER stress pathways are still poorly understood.
Thesemechanisms appear to be specifically linked to conditions
in vivo because cultured cells seem to recruit the fullblown UPR
repertoire upon stressors (Rutkowski and Hegde, 2010). With
respect to neurons, enhanced physiological demands likely
include phases of axonal and dendritic growth, synaptogenesis,
and synaptic plasticity, as well as major alterations in excitability
and calcium fluxes. Accordingly, cell type-specific intersections
between physiological demands, the misfolding of specific
proteins, and agemay assign central roles to ER stress pathways
in defining selective neuronal vulnerabilities and driving progres-
sive dysfunctions in NDDs (Matus et al., 2011).
Mechanisms that Target Neurons in NDDs
Accumulation of Misfolded Proteins
The majority of proteins comprise structured domains joined by
potentially flexible linkers. By contrast, Ab, tau, a-synuclein, and
polyglutamine proteins involved in NDDs belong to the intrinsi-
cally disordered proteome, i.e., they are proteins with little stable
three-dimensional structure in physiological solutions, which
tend to assume stable folds upon interactions with other
proteins. The corresponding misfolded species expose compa-
rable beta sheet stretches particularly prone to protein interac-
tions. These interactions are thought to involve regulatory protein
complexes, possibly accounting for a ‘‘dominant’’ misregulation
of multiple interconnected pathways in affected cells (e.g., Gida-
levitz et al., 2006; Haass and Selkoe, 2007; Winklhofer et al.,
2008; Williams and Paulson, 2008; Roth and Balch, 2011). For
example, such interactions can saturate binding sites of scaffold
proteins important for cell regulation or can sequester heat-
shock proteins such as Hsc/p70 and Hsp40 important to main-
tain proteostasis and prevent disease (e.g., Roth and Balch,
2011). It seems likely that for each misfolding-prone protein
certain types of neurons are more affected by how that protein
disrupts cellular protein networks, and this may contribute to
their selective vulnerability to a particular NDD (Figure 1). Indeed,
consistent with dominant interference in subsets of neurons,
genetic studies in C. elegans have provided evidence that
disease-related human proteins such as a-synuclein preferen-
tially form aggregates in certain worm neurons, where they
enhance the vulnerability of the same neurons to misfolding-
prone protein species such as constructs with subthreshold pol-
yglutamine stretches (Brignull et al., 2006; Lim et al., 2008).
Furthermore, mutant misfolding proteins associated with familial
forms of NDDs can, at least to some extent, model the same
diseases when expressed ubiquitously in evolutionarily distant
model organisms such as zebrafish or Drosophila (e.g., Lessing
and Bonini, 2009; Sheng et al., 2010; Xia, 2010). These studies
are consistent with the notion that disease-associated misfold-
ing proteins each interfere with cellular signaling and proteosta-
sis networks in their own specific manners, thereby affecting
preferentially particular subtypes of neurons whose properties
are evolutionarily conserved.
Notably, the accumulation of misfolding proteins is often not
sufficient to cause disease, and studies of human populations
suggest how additional factors have to combine with the age-
related accumulation of misfolding proteins for disease to38 Neuron 71, July 14, 2011 ª2011 Elsevier Inc.develop. Thus, the same types of characteristic macroscopic
deposits can accumulate in the same neurons or the same brain
regions in some but not all aging brains in the absence of major
disease manifestations (Jellinger, 2004; Brignull et al., 2006;
Kern and Behl, 2009; but see Sperling et al., 2009; Hedden
et al., 2009). Recent studies have provided intriguing insights
into how deposit accumulation may relate to dysfunction in the
absence or presence of disease. The studies combined amyloid
and functional brain imaging and revealed that agedpersonswith
deposits, but without noticeable AD, exhibit cognitive deficits
involving cortical ‘‘default networks,’’ i.e., cortical areas that are
active even when the brain is not engaged and which may be
involved in off-line processing. Comparable impairments were
detected in patients with mild cognitive deficits, which frequently
progress to develop full-blown AD, suggesting that the amyloid
depositsmaybeassociatedwith very early stagesofAD (Sperling
et al., 2009; Hedden et al., 2009). Such early stages may not
necessarily progress to AD, and the mechanisms underlying
disease conversion remain to be determined. Interestingly, how-
ever, early-onset AD patients with more rapid disease progres-
sion readily exhibit deposits paired with signs of local hypoactiv-
ity (reduced glucose utilization), whereas late-onset patients
initially exhibit deposits paired with only very subtle signs of
cognitive dysfunction (e.g., Rabinovici and Jagust, 2009). One
possible interpretation of these findings is that neuronal
responses linked to hypoactivation may synergize with deposit
toxicity to precipitate disease. By extension, large fractions of
the human population may develop amyloid deposits and mild
cognitive impairments late in life without progressing to AD.
These findings are consistent with the notion that toxic Ab is crit-
ically important to AD but suggest that additional dysfunction
processes that aggravate Ab -dependent toxicity and promote
misfolded tau accumulation are required to cause disease; the
additional dysfunctions may develop more readily in the more
aggressive early-onset forms of AD. Aging but only partially
compromised neurons may be more resistant to the misfolded
species and may more effectively neutralize toxic oligomeric
species to form nontoxic macroscopic aggregates (Arrasate
et al., 2004). By the same reasoning, familial casesof thediseases
may augment the likelihood of disease conversion due to mutant
protein versions more prone to cellular toxicity and misfolding.
A further important aspect relating misfolding proteins to
particular NDDs is that several disease-associated misfolding
proteins, e.g., tau, a-synuclein, and TDP-43, are implicated
causally in NDDs with different pathological and clinical manifes-
tations and affecting different parts of the nervous system. The
mechanisms that underlie this striking feature of NDDs are
currently not clear. However, one possibility consistent with
current findings and with a stressor-threshold model of NDD
etiology is that genetic predisposition and environmental factors
may influence the initiation of NDDs with distinct manifestations
and involving different neuronal systems (first level of specificity)
and that the misfolding proteins may be critical cofactors that
can promote neurodegeneration within a few specific potential
neuronal settings (second level of specificity) (Figure 1).
Stress- and Age-Related Pathways
Given the critical involvement of protein misfolding processes,
and the trans-effects involved in their toxicity, it is not surprising
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ciated with NDDs. Indeed, ER stress and unfolded protein
response (UPR) markers are consistently upregulated in CNS
samples from patients suffering from familial or sporadic
NDDs, and the same pathways are already activated at pre-
clinical phases in animal models of the diseases (Malhotra and
Kaufman, 2007; Rutkowski and Kaufman, 2007; Matus et al.,
2011). Likewise, UPS and autophagy pathways have also been
implicated in most NDDs (Komatsu et al., 2006; Finkbeiner
et al., 2006; Morimoto, 2008). Notably, studies in genetic model
organisms have provided evidence that ER stress, UPS and au-
tophagy pathways do not just correlate with pathology and neu-
rodegeneration, but are causally related to their progression.
Thus, mice deficient in the autophagy protein Atg5 exhibited
cytoplasmic inclusions and signs of neurodegeneration (Hara
et al., 2006), absence of Atg7 in mice caused massive neurode-
generation and premature death (Komatsu et al., 2006), and
deletion of the BH3-only protein Puma, an ER stress protein,
had protective effects on motoneurons in a mouse model of
ALS (Kieran et al., 2007). These findings have led to the notion
that NDDs may involve cell-specific interplays between protein
misfolding and cellular stress pathways (Figure 1). Because the
effectiveness of the cell homeostasis pathways is known to
diminish with advancing age, their involvement in NDDs ties in
well with the age dependence of the neurodegenerative
processes.
In further support of a close mechanistic relationship between
cell homeostasis and protein misfolding pathways in NDDs, the
signaling pathways that relate life span and aging to organelle
and energy homeostasis powerfully influence the accumulation
of misfolded proteins and the effectiveness of cell stress path-
ways (Gan and Mucke, 2008; Prahlad and Morimoto, 2009;
Cohen et al., 2009). Groundbreaking studies in C. elegans have
established that the effector of the Insulin/IGF1 pathway
Daf16, which regulates longevity, also regulates the expression
of HSF1 (heat shock factor 1) chaperons that control protein
homeostasis in response to misfolding-induced stress (Morley
et al., 2002; Hsu et al., 2003). Furthermore, starvation and inhibi-
tion of the Insulin/IGF1 pathway promote autophagy pathways
thought to directly promote longevity (Hsu et al., 2003). Perhaps
most interestingly in the context of NDDs, inhibiting IGF1
signaling diminishes age-related proteotoxicity in mice (Cohen
et al., 2009), and activation of the Insulin/IGF1 pathway pro-
motes the accumulation of human Ab aggregates in C. elegans,
thus linking universal aging-related pathways with the accu-
mulation of misfolded proteins implicated in AD in humans
(Hsu et al., 2003; Prahlad and Morimoto, 2009). Along similar
lines, an age-related decline in the PGC1a (peroxisome prolifer-
ator-activated receptor gamma coactivator 1-a) pathway that
promotes cell plasticity, mitochondrial biogenesis, and energy
production is causally related to increasing ER stress, increasing
accumulation of misfolding proteins, and accelerated disease
progression in animal models of NDDs (St-Pierre et al., 2006;
Weydt et al., 2006; Cui et al., 2006).
Taken together, these findings delineate a rich set of intercon-
nected signaling pathways potentially linking advancing age,
impaired protein homeostasis, ER stress, and mitochondrial
dysfunction to the accumulation of particular misfolded proteinsand neurodegeneration. Since these pathways have all been
related through genetic studies to neurodegeneration in animal
models, dissecting the actual sequences of causal events that
promote the initiation and progression of neurodegenerative
processes in any specific NDD is critically important to elucidate
mechanisms of disease.
Dissection of Disease Processes In Vivo
Earliest DiseaseRelevant Processes in FALS Mice
To investigate causal relationships in NDD models, it is useful to
determine which are the earliest disease-related processes and
whether their progression can be linked to the onset of clinical
symptoms. This logic has been pursued extensively in mouse
models of ALS, where the ages at which dysfunctions become
detectable and the rates at which they progress can be pre-
dicted within 2–4 days. That allows a near to longitudinal
approach to investigating diseasemechanisms, which is of great
help to elucidate issues of causality.
In transgenic mutant SOD1 mice, point mutants of human
SOD1 responsible for familial ALS (FALS) are overexpressed
using human minigenes (Gurney et al., 1994; Wong et al.,
1995). Although the transgene is expressed at comparable
levels throughout the CNS, mice develop motoneuron disease
with features closely comparable to late-onset ALS in humans.
In one line of transgenic mice (G93A-fast), mice exhibit first
clinical signs of muscle weakness at postnatal day (P) 80–90,
and die at P135 (Gurney et al., 1994). A second line of mice over-
expressing the same G93A mutant, but at lower levels (G93A-
slow) exhibit clinical signs of weakness at P170–200 and die at
P250–270, whereas transgenic mice overexpressing yet lower
levels of the same mutant do not get motoneuron disease (Boil-
le´e et al., 2006b). Therefore, mice can cope with some levels of
the mutant protein without developing disease, and varying the
levels of the samemisfolding-prone species is sufficient to deter-
mine the onset time of motoneuron disease.
Spinal cord preparations from early postnatal mutant SOD1
transgenic mice exhibit a persistent pronounced hyperexcit-
ability of motoneurons and a transient deficit to produce alter-
nating ventral root activity (Bories et al., 2007). Hyperexcitability
was also found in several types of neurons in neonatal mutant
SOD1 transgenics and in dissociated motoneuron cultures
from transgenic embryos (Bories et al., 2007; van Zundert
et al., 2008). To date, these findings document the earliest known
deficits in these ALS mice, suggesting that imbalances in the
excitation of motoneurons are very early abnormalities in
a disease background. Hyperexcitability of upper and lower
motoneurons figures prominently in sporadic and familial cases
of ALS, suggesting that it may be a major feature of motoneuron
dysfunction in ALS (e.g., Vucic et al., 2008). Enhanced excit-
ability has also been related to susceptibility to disease in HD
(Zeron et al., 2002; Garcia et al., 2007), PD (Chan et al., 2007),
and AD (Palop et al., 2007; Busche et al., 2008) models, suggest-
ing that it may be amajor and currently understudied factor influ-
encing the development of NDDs.
Systematic studies of hindlimb muscle innervation in mutant
SOD1 mice have revealed how the muscle fibers innervated by
the most phasic functional subtypes of motoneurons (fast-
fatiguable [FF] motoneurons) all become abruptly denervatedNeuron 71, July 14, 2011 ª2011 Elsevier Inc. 39
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et al., 2000; Pun et al., 2006). The other subtype of phasic moto-
neurons (fast fatigue-resistant (FR) motoneurons) disconnect
from their muscle fibers in late presymptomatic mice (P80–90
in G93A-fast mice), and tonic motoneurons (slow [S] motoneu-
rons) only disconnect around endstage (Pun et al., 2006).
Notably, mutant SOD1 mouse strains developing clinical signs
and death later in life exhibit the same temporal patterns of
selective denervations, except for a corresponding shift in the
time of the early FF denervations (Pun et al., 2006). A detailed
longitudinal investigation of the transcriptome of these moto-
neuron subtypes in mutant SOD1 mice revealed that the most
vulnerable FF motoneurons exhibit signs of ER stress and upre-
gulate ER chaperons already at the end of the third postnatal
week, when no signs of glial or vascular alterations have yet
been reported in these mice (Saxena et al., 2009). Depending
on the particular mutant SOD1 strain and mutant protein levels,
signs of compensated ER stress augment at different rates, to
reach a comparable level 20 days before FF denervation, when
a UPR is initiated in these motoneurons. This is also the time
when first signs of microglial activation were detected in these
mice. Lesions to the vasculature were also detected early on in
the FALS mice (Zhong et al., 2008). Interestingly, FR motoneu-
rons only exhibit increasing ER chaperons levels around this
transition time, and then go on to develop a UPR 20–30 days
before disconnection of their peripheral synapses to muscle
(Saxena et al., 2009).
Peripheral nerve crush experiments in wild-type and mutant
mice established that FF motoneurons are selectively vulnerable
to ER stress, suggesting that their selective vulnerability in ALS
may reflect an intrinsic vulnerability of these highly phasic moto-
neurons to stressors (David et al., 2007; Saxena et al., 2009).
Interestingly, a premature crush-induced UPR in vulnerable
motoneurons of mutant SOD1 mice subsided upon sucessful
regeneration, suggesting that when they are induced at a prema-
ture age elevated stressor levels in motoneurons do not accel-
erate disease (Saxena et al., 2009).
The combined findings from longitudinal studies in FALS
mice suggest a model whereby sustained and growing ER stress
in vulnerable neurons has a role in increasing net stressor levels,
thus promoting disease progression from its earliest stages
(Figure 1). This might imply the existence of at least two
disease-related processes in these FALS mice: first, the pres-
ence of mutant SOD1 in neurons and nonneuronal cells may
produce an age-related increase in stressor levels (e.g., an im-
balance in protein networks and/or in synaptic functions) inmoto-
neurons and possibly further vulnerable cells in the mutant mice;
second, in the most stress-sensitive motoneurons this produces
an increasing ER stress load, which eventually augments
disease-relatedviciouscycles that promotediseaseprogression.
In sporadic cases of ALS, instead of being provided by mutant
protein overexpression, the increased stressor levels may for
example involve lesions leading to hyperexcitation of motoneu-
rons, followed by comparable mechanisms of disease progres-
sion related to ER stress. Surprisingly, in spite of the very early
ER stress processes within vulnerable motoneurons in the
FALS mice, overexpression of mutant SOD1 only in neurons did
not cause signs of disease in transgenic mice (e.g., Lino et al.,40 Neuron 71, July 14, 2011 ª2011 Elsevier Inc.2002; Clement et al., 2003). These results suggest the existence
of yet unidentified additional effects of mutant SOD1 on non-
neuronal cells that must have an early impact on spinal moto-
neurons before the onset of known disease-related pathology.
Transitions and Accelerated Disease Progression
Although most NDDs manifest in middle or old age, they can
progress rapidly from the first appearance of clinical signs.
Cases with a familial component often manifest several years
earlier and progress more rapidly than the sporadic cases. In
addition, early-onset sporadic cases tend to progress more
rapidly than the late-onset ones. Furthermore, and perhaps not
unlike cancer, there may be early lesions in NDDs that can, but
not necessarily do progress to full-blown disease. Consistent
with this notion, in individuals carrying the Epo-E4 allele amyloid
pathology was detected decades before the expected clinical
onset of AD, and with frequencies of >40% in individuals aged
50 to 59 years, i.e., substantially higher than the expected
frequencies to develop AD (Kok et al., 2009). Oneway to account
for these observations would be to hypothesize that there may
be distinct transitions during the course of NDDs, possibly
reflecting the existence of ‘‘disease onset times,’’ which would
be followed by disease progression. More aggressive prodromal
forms, including all the familial forms, may have a higher con-
version rate to disease onset and progression. However,
although the concept has appealing features, andmay be impor-
tant to understand and treat these diseases, the nature and
indeed existence of such qualitative transitions in the disease
process are poorly understood.
One line of evidence supporting the notion of disease transi-
tions involves the studies in mutant SOD1models of ALS, where
an abrupt transition to a UPR in FF motoneurons coincides in
time with the local activation of CD11-positive microglia, and
with signs of increasing ER stress in less vulnerable FRmotoneu-
rons (Saxena et al., 2009). A plausible scenario may be that the
resident activated microglia (and/or additional local cell types)
may eventually have a role in promoting disease accentuation
and spreading. Such a possibility would be consistent with
results implicating mutant microglia in disease progression in
the ALSmice (Clement et al., 2003; Boille´e et al., 2006a; Lobsiger
and Cleveland, 2007; Harraz et al., 2008; Gowing et al., 2009;
Appel et al., 2010). Microglia have also been implicated in
presymptomatic HD (Bjo¨rkqvist et al., 2008), PD (Tansey et al.,
2007), AD (Simard et al., 2006; Bolmont et al., 2007; but see
also Grathwohl et al., 2009), and tauopathies (Yoshiyama et al.,
2007). Disease-related vasculature lesions (Zlokovic, 2005;
Vermeer et al., 2003; Bell et al., 2009; Zhong et al., 2008) may
also worsen at this time. Furthermore, the onset of a UPR in vivo
has been generally linked to the initiation of inflammatory
processes (Zhang and Kaufman, 2008). Although resident
inflammatory cells are thought to have beneficial effects as a first
line of defense in diseases of the nervous system (Ron-Harel and
Schwartz, 2009; Appel et al., 2010; Bjo¨rkqvist et al., 2009),
inflammatory cell recruitment in a NDD background may have
immediate adverse effects in promoting disease progression
(e.g., Kang and Rivest, 2007; Zhao et al., 2010; Glass et al.,
2010). In an example for beneficial effects, FALS mice with
bone marrow cells lacking the myeloid differentiation factor
Myd88 and thus reduced inflammatory response exhibited
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wise, functional circulating monocytes can delay the onset of
cognitive deficits and Ab accumulation in AD model mice (Naert
and Rivest, 2011). However, initially restorative processes may
evolve into adverse ones either due to chronic inflammation
paired to reduced systemic immune involvement or due to accel-
erated spreading of the disease through vascular routes (Ron-
Harel and Schwartz, 2009). Taken together, the evidence from
NDDs patients and from NDD models suggests that a patholog-
ical involvement of the local environment in the CNS, e.g.,
through inflammation or vascular lesions, may be an important
mechanism through which prodromal lesions in vulnerable
neurons may convert to full-blown NDD.
Spreading of Misfolded Proteins
NDDs can involve local initiation processes followed by
spreading to yet unaffected parts of the nervous system. This
can involve inflammation, the immune system, and the vascula-
ture, but also spreading of the misfolded proteins themselves
(e.g., Mackic et al., 2002; Decarli, 2004; Cole and Vassar,
2009). For example, recent studies have provided dramatic
evidence for spreading of extracellular misfolded Ab species,
suggesting that AD may involve the seed-like dissemination of
toxic protein species through the vasculature and/or neuronal
processes (Mackic et al., 2002; Meyer-Luehmann et al., 2003;
Meyer-Luehmann et al., 2006; Bolmont et al., 2007;Meyer-Lueh-
mann et al., 2008; Eisele et al., 2010). Spreading has also been
reported for misfolded tau in vitro (Frost et al., 2009) and in vivo
(Clavaguera et al., 2009), for misfolding mutant SOD1 (Urushitani
et al., 2008), and for Lewy bodies and misfolding a-synuclein
(Brundin et al., 2008; Lee et al., 2005; Desplats et al., 2009).
In addition to spreading through extracellular space and
systemically, NDDs can spread through axonal projections,
leading to specific patterns of dissemination through intercon-
nected systems. For example, prions and some amyloid species
can spread through axons, whereas other amyloid species
target the vasculature (Aguzzi and Calella, 2009; Frost and
Diamond, 2010). Furthermore, synuclein-based deposits have
been suggested to accumulate according to a complex pattern,
involving intestinal, olfactory, andmedullar circuits before target-
ing midbrain nigral neurons, and this could in principle involve an
axonal spreading mechanism (Hawkes et al., 2007).
With respect to stressor-threshold models of disease, the
likely implication of systemic factors and spreading mecha-
nisms in the progression of NDDs may provide a key mecha-
nistic element to account for the fact that most NDDs gradually
spread across brain systems and that familial and sporadic
forms of NDDs manifest with closely comparable progressions
of dysfunctions and pathology. Disease-promoting reciprocal
interactions between pathological processes in selectively
vulnerable neurons and in the microenvironment in the CNS
may provide a basis for the establishment and spreading of
degenerative processes to non-affected parts of the nervous
system and to less vulnerable neurons in the absence of
disease-causing mutations (Figure 1).
Selective Vulnerabilities of Affected Neurons in NDDs
We finally discuss the evidence that the neurons most affected
by a particular NDD are selectively vulnerable to specificstressors, which may influence the accumulation of disease-
associated misfolding proteins, thus underlying the onset and
progression of that disease.
Parkinson’s Disease
Dopaminergic (DA) substantia nigra pars compacta (SNc)
neurons, whose dysfunction and loss account for the major clin-
ical manifestations of PD, appear to be particularly vulnerable
to mitochondrial dysfunction (e.g., Biskup and Moore, 2006).
This has prompted investigations trying to relate aging, mito-
chondrial respiratory chain dysfunction, and ROS levels to PD.
Sporadic PD patients were found to exhibit specific complex 1
deficits in SNc DA neurons (Gu et al., 1997), and rats treated
subcutaneously with themitochondrial complex 1 inhibitor Rote-
none exhibited enhanced reactive oxygen species levels in the
SNc (Keeney et al., 2006), as well as signs of parkinsonism,
with loss of DA SNc neurons, and accumulation of Lewy bodies,
the protein deposits characteristic of PD (Sherer et al., 2003). This
is in principle an important result as it suggests that enhancing
mitochondrial stress systemically not only selectively affects
DA SNc neurons but also leads to the accumulation of disease-
related deposits. However, defining the actual causal relation-
ships involving mitochondria and relevant to disease turned out
to be more challenging. Thus, experiments directly testing mito-
chondrial function in hybrid cell lines provided evidence against
a direct role for complex 1 dysfunction in PD (Choi et al., 2008;
Fukui and Moraes, 2008). Further investigations suggested that
disease-related mitochondrial dysfunction may involve disrup-
tions in mitochondrial dynamics processes (Vives-Bauza et al.,
2010; for similar conclusions on mitochondrial dysfunction in
AD, see Cho et al., 2009; for a critical review, see Fukui and
Moraes, 2008). The upshot of these studies is that elevated
ROS levels and mitochondrial dysfunction in DA SNc neurons
are clearly associated with PD. Mitochondrial vulnerability might
be a first hit target, predisposingDASNc neurons for vulnerability
to PD, but the mitochondrial respiratory chain dysfunctions may
be an aggravating consequence rather than a cause of disease.
Further supporting the notion that a selective vulnerability of
DA SNc neurons to PD is linked to mitochondrial dysfunction,
genes whose mutations are causally related to PD code for
proteins that either accumulate at mitochondria (Pink1, DJ-1,
Htra2, LRRK2), are implicated inmitochondrial functionality (Par-
kin), or influence each other’s role in disease (Parkin and a-syn-
uclein, Parkin and Pink1; e.g., Bogaerts et al., 2008; Banerjee
et al., 2009). However, like for the pharmacological evidence, it
is not clear whether the genes cause PD by specifically impairing
mitochondrial functions. For example, studies of a-synuclein
function have provided evidence that this protein has a critical
role as a chaperone for SNARE assembly, and in regulating
synaptic vesicle cycling (e.g., Nemani et al., 2010; Burre´ et al.,
2010). The mechanistic relationship between a-synuclein muta-
tions and PD may thus involve synaptic transmission and excit-
ability. Likewise, DJ-1 has a role as oxidative stress sensor, and
Parkin also has a role in stress protection (e.g., Banerjee et al.,
2009; Guzman et al., 2010), suggesting that the relationship
between these genes and PD may involve cellular stress path-
ways. The etiology of PD may thus involve overburdening of
stress pathways involving mitochondria, which are particularly
sensitive in DA SNc neurons.Neuron 71, July 14, 2011 ª2011 Elsevier Inc. 41
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drial dysfunction than other neurons? Studies addressing the
excitability properties of PD-vulnerable neurons have provided
exciting evidence as to how this vulnerability may come about.
The studies show that adult DA SNc neurons are Ca-dependent
pacemakers whose intrinsic activity is driven by Cav1.3 low
voltage-dependent L-type Ca-channels (Chan et al., 2007).
These particular channels open at relatively hyperpolarized
membrane potentials, leading to high Ca flux loads in DA SNc
neurons. Notably, reducing Ca load with L-type Ca channel
antagonists reduced the susceptibility of the SNc neurons to
parkinsonism-inducing drugs (Chan et al., 2007). A recent study
provided evidence that the pacemaking produces oxydative
stress selectively in SNc dopaminergic neurons (Guzman et al.,
2010). The oxydative stress is compensated by partial uncou-
pling of mitochondria, which is impaired in the absence of DJ-1
(Guzman et al., 2010). Consistent with the notion that Ca over-
load has an important role in disease, a mtDNA polymorphism
that compromises the ability of mitochondria to accumulate Ca
is a risk factor in PD (Autere et al., 2004). Furthermore, and
consistent with a critical role of Ca influx in the etiology of PD,
a recent study provided evidence that L-DOPA-induced Ca
influx through dihydropyridine-sensitive Ca channels led to
enhanced cytosolic levels of dopamine in DA SNc neurons,
which causes a-synuclein-dependent death of these neurons
(Mosharov et al., 2009). In addition to mitochondria, ER com-
partments also have a major role in regulating Ca fluxes and
sequestering Ca from the cytosol, providing for extensive poten-
tial crosstalk between Ca overload, mitochondrial dysfunction
and ER stress in PD (e.g., Sulzer, 2007). Oxydative stress related
to pacemaking and mitochondrial Ca load may thus be a causal
factor in PD, specifically in DA SNc neurons.
Alzheimer’s Disease
The neurons at higher risk in AD, including entorhinal cortex and
hippocampal CA1 projection neurons are particularly vulnerable
to decreased glucose and oxygen delivery through the vascula-
ture and thus to energy deprivation (Hof and Morrison, 2004).
Indeed, in early-onset cases, mild cognitive deficit conditions,
which frequently progress to AD, correlate with reduced glucose
utilization in the brain (Reiman et al., 2004; Mosconi et al., 2008;
Rabinovici and Jagust, 2009). In addition, synaptic transmission,
ER stress, and Ca homeostasis have been implicated as major
targets of disease in AD (Bezprozvanny and Mattson, 2008;
Dreses-Werringloer et al., 2008).
How may energy deprivation specifically relate to the molec-
ular processes that have been causally associated to AD?
Energy deprivation is a stress factor that can induce Pi-eIF2a,
which in turn produces elevated levels of BACE1 translation,
the beta-secretase whose levels are enhanced in AD and in
animal models of aging, and which is necessary to generate Ab
(Yang et al., 2003; Lammich et al., 2004; Velliquette et al.,
2005; O’Connor et al., 2008; Vassar et al., 2009). Along similar
lines, neuronal BACE1 levels are elevated by several cellular
stress pathways, and by inflammation, again relating cellular
stress to Ab production. In turn, several studies have provided
compelling experimental evidence that extracellular Ab is toxic
to synapses (e.g., Selkoe, 2008). Furthermore, Alzheimer
precursor protein (APP) processing leading to Ab production42 Neuron 71, July 14, 2011 ª2011 Elsevier Inc.can also lead to the production of an extracellular amino-terminal
fragment of APP, which can induce axon degeneration upon
growth factor deprivation by activating the death receptor DR6
(Nikolaev et al., 2009). In possibly related findings, neurons
exposed to Ab exhibit enhanced cytosolic Ca levels and
enhanced vulnerability to excitotoxicity (e.g., Meyer-Luehmann
et al., 2008), and mouse models of AD exhibit enhanced excit-
ability in cortex and hippocampus (Palop et al., 2006). The path-
ways leading to full-blown AD may thus involve hyperexcitation
and Ca overload. Further relating AD to cellular Ca loads, AD-
related mutations in presenilin (the gamma-secretase that
produces Ab) enhance Ca release from the ER, which can lead
to higher Ab processing (Tu et al., 2006; Cheung et al., 2008).
In addition, BACE1 regulates Nav ion channel levels, a major
factor in neuronal excitability (Kim et al., 2007). Finally, further
relating cell stress to AD, the stress-related second messenger
ceramide can promote Cdk5-mediated phosphorylation of
tau, which promotes clustering of mitochondria with the ER,
enhancing mitochondrial uptake of Ca (Darios et al., 2005;
Wen et al., 2008). Taken together, these observations delineate
possible disease pathways relating energy deficits and neuronal
stress to enhanced BACE1 and Ab, and on to synapse loss,
network dysregulation, hyperexcitability, further neuronal stress,
and the accumulation of tau-based tangles in the neurons most
vulnerable to AD.
Huntington’s Disease
With respect to corticostriatal involvement in HD, one selective
vulnerability appears to involve the connectivity properties of
striatial medium-sized spiny neurons, which again express
Cav1.3 channels, and whose excitation is controlled by a com-
bination of glutamatergic inputs from neocortex and dopami-
nergic inputs from SNc (Bamford et al., 2004; Cepeda et al.,
2007). The cortical projections exhibit early hyperexcitation in
HD, apparently leading to a toxic convergence of glutamate
and dopamine signals onto the medium-sized spiny neurons,
further enhancing their vulnerability to mutant Huntingtin (Sur-
meier et al., 2007). This scenario highlights the potential impor-
tance of non-cell-autonomous and circuit-based mechanisms
to account for selective vulnerability in NDDs (for a conceptually
related study in C. elegans, see Garcia et al., 2007). Mutant Hun-
tingtin may have similar disrupting effects on several types of
neurons and nonneuronal cells, e.g., by selectively interfering
with the expression of important genes such as BDNF (Zuccato
et al., 2001) andPGC1a (Chaturvedi et al., 2009). Reduced BDNF
may impair adaptive plasticity, whereas a deficit in inducing
PGC1a expression upon stress load compromises cellular adap-
tation to stress protection and to enhanced mitochondrial
demand. Indeed, PGC1a levels are selectively reduced in striatal
medium spiny neurons, and energy deficits are a prominent and
early manifestation of disease in HD. The combination of these
dysregulations in afferent and target neurons may aggravate
excitotoxicity selectively in striatal medium-sized spiny neurons.
Amyotropic Lateral Sclerosis
Specific combinations of high intrinsic neuronal vulnerabilities to
stress, and stress-generating connectivity properties also seem
to account for the selective vulnerability of motoneurons in ALS.
Thus, spinal motoneurons vulnerable to ALS are particularly
prone to hyperexcitation due to their low expression of GABAA
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neurons consistently not affected by this disease (e.g., oculo-
motor neurons) by their very low levels of cytosolic Ca buffering
proteins, and their adaptation for rapid Ca signaling in order to
produce high-frequency spiking (Siklo´s et al., 1998; Vanselow
and Keller, 2000; von Lewinski and Keller, 2005). In addition,
motoneurons depend on neuromodulatory activity acting via
the activation of low voltage-gated ion channels such as
Cav1.3, further enhancing Ca loads in order to produce spiking
activity. The absence of intracellular Ca buffers renders these
neurons particularly dependent on mitochondria for regulating
cytosolic Ca transients, which predisposes them for excitotoxic
vulnerability upon mitochondrial impairments (Rothstein, 1995–
1996; Verkhratsky, 2005; von Lewinski and Keller, 2005; Browne
et al., 2006; Spa¨t et al., 2008; Teuling et al., 2007; Atkin et al.,
2008; Urushitani et al., 2008). Taken together, motoneurons
affected in ALS are particularly prone to excitotoxicity, cellular
damage due to Ca overload, and cell stress.
Consistent with a role for these selective vulnerabilities in ALS,
elevated persistent inward currents were detected early in corti-
cospinal and in spinal motoneurons in ALS models and in aging
motoneurons, supporting the notion that these are involved in
the disease process (Kuo et al., 2005). Mutant SOD1 specifically
associates with motoneuron ER andmitochondria and interferes
with their function in ALS; accordingly, ER stress and mitochon-
drial pathology have been detected early in ALS model mice
(Kong and Xu, 1998; Liu et al., 2004; Pasinelli et al., 2004; Ferri
et al., 2006; Vande Velde et al., 2008). Furthermore, VAPB has
a role in the ER stress response, and VAPBmutations associated
with familial ALS predispose to ER stress (Teuling et al., 2007;
Kanekura et al., 2009). Cell stress pathways may also account
for how mutations in the RNA-binding proteins TDP-43, FUS
and VCP lead to sporadic and familial ALS (Sreedharan et al.,
2008; Kwiatkowski et al., 2009; Gitcho et al., 2009; Johnson
et al., 2010). Thus, the three proteins interact functionally, and
VCP is involved in ubiquitin-dependent protein degradation
and cell stress. In sum, mutations associated with familial ALS
appear to enhance the sensitivity of motoneurons to stressors,
supporting the notion that cellular stress has an important role
in the etiology of ALS. Interestingly, the most vulnerable, highly
phasic, motoneurons exhibit lowest membrane excitability pro-
perties, thus rendering them particularly inefficient to produce
spiking activity under a regime of reduced synaptic and/or mito-
chondrial function (Siklo´s et al., 1998). This may account for
compensatory hyperexcitability, which in a disease setting is
particularly prominent in these motoneurons, setting them up
for greater cytosolic Ca overloads upon recruitment, and thus
enhanced vulnerability to stressors.
Summary
Although generalizations should be considered with caution at
this point, selective neuronal vulnerability in PD, AD, HD, and
ALS seems to share two main features. First, selectively vulner-
able neurons exhibit unusual excitability properties coupled to
high calcium fluxes under physiological conditions, and exhibit
hyperexcitability in disease. Second, several of the genes that
have been linked to familial forms of the diseases have roles in
stress regulatory pathways and/or in the regulation of synaptic
function and transmitter release. Considering how the regulationof synaptic plasticity and excitability in neurons may interface
with ER stress pathways, these early indications suggest that
NDDs may involve competitive crosstalk between pathways
thatmaintain synaptic functions, excitability, andenergybalance,
and those that counteract protein misfolding in aging neurons.Outlook
The current evidence regarding the neurons most affected in
NDDs suggests that disturbances leading to persistent shifts
in excitation may represent a major class of first hits along
a path to neurodegeneration. In combination with chronic inflam-
mation and/or vascular lesions, this may raise stressor levels
in and around vulnerable neurons. This, in turn, may augment
the levels of disease-related misfolded proteins, and at the
same time impair pathways important to maintain proteostasis
balances in vulnerable neurons. Vicious cycles between neu-
ronal stressors and disease-related misfolding-prone proteins
may then drive age-related dysfunction in vulnerable neurons.
Elucidating how individual disease-related misfolding proteins
are associated with particular NDDs will require further studies,
but the current evidence is consistent with the existence of
specific mechanistic associations between subsets of stressors,
subsets of misfolding-prone proteins, and subsets of vulnerable
neurons (Figure 1).
A stressor-threshold model of selective neuronal vulnerability
and of the role of neuronal vulnerability in disease is consistent
with a large body of observations in patients and in animal
models. However, important causality issues remain to be ad-
dressed. These include the roles of increasing ER stress in trig-
gering disease, the role of alterations in neuronal excitability in
disease, whether and to what extent alterations in neuronal
excitability influence ER stress, and the role of misfolding protein
acumulation in triggering disease. Furthermore, disease process
scenarios in which processes in selectively vulnerable neurons
are mainly considered as consequences rather than causes in
the etiology of disease have also been discussed. Ultimately,
testing the role of selective neuronal vulnerabilities for the
etiology of NDDs will require cell specific and conditional models
of these diseases, possibly in combination with environmental
factors that may be needed to trigger disease.
Critical issues to address in future experiments include the
following:
 Selective vulnerability and neuronal excitability: do specific
connectivity and excitability properties of neuronal sub-
populations have a key role in their selective vulnerability
to NDDs?
 Misfolding proteins and selective vulnerability: are subpop-
ulations of neurons affected in disease particularly sensi-
tive to the toxicity of relevant misfolding proteins, and
what are the underlying mechanisms; does this sensitivity
lead to vicious cycles of increasing stressor load and
increasing misfolding protein accumulation in the vulner-
able neurons?
 Misfolding protein accumulation in sporadic forms of the
diseases: do environmental stressors targeting vulnerable
neurons lead to the accumulation of disease-related mis-
folding proteins in those neurons?Neuron 71, July 14, 2011 ª2011 Elsevier Inc. 43
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predicts that it should be possible to produce animal mo-
dels of the sporadic forms of the diseases, e.g., through
combinations of environmental stressors and sensitizing
genetic backgrounds.
 Conversion to degenerative disease: what factors deter-
mine whether mild dysfunctions associated with disease-
related deposits progress to neurodegeneration, and are
cell specific stressor-load thresholds critically involved;
does conversion depend on disease-related processes in
the local CNS environment?
 Role of vascular lesions, inflammation, and immune system
involvement: are systemic factors necessary, andmay they
even be sufficient to cause disease?
A stressor-thresholdmodel of NDDs has potential implications
for therapeutic strategies. Since advancing age gradually
increases stressor load as long as underlying causes are
present, strategies targeting cellular stressor pathways should
aim at processes that are critical to drive vicious circles of
increasing cellular stress and misfolding protein acumulation.
Such critically important stressors may be identified through
modifier screens in genetic model organisms and patient-
derived stem cells, as well as through sequencing strategies in
selected groups of patients. Potential targets may include
specific regulators of neuronal excitability, and reagents to
reduce the accumulation of specific misfolding species,
such as chaperon-like molecules or specific antibodies. Key
disease-relevant processes may differ among NDDs, and
possibly also among NDD subtypes, suggesting that it may be
important to establish and apply sensitive biomarkers of disease
subtypes.
Should conversion processes indeed be critical to progress
from prodromic dysfunction to advancing degeneration, then
these would be potentially valuable targets for treatments, as
they may prevent, and possibly even reverse conversion to
disease. Candidate targets may involve local interactions within
the neuronal environment in the CNS, e.g., inflammatory
processes and/or vascular lesions.
Finally, at least in sporadic forms of the diseases, effective
treatments may target disease spreading, thereby restricting
degeneration to CNS regions initially affected by disease. Again,
potential targets include vascular integrity, inflammation, and the
immune system, and interventions aimed at reducing extracel-
lular misfolding protein levels, e.g., through specific antibodies.
An evaluation of the potential value of such treatment strate-
gies in well characterized animal models of NDDs should at the
same time represent a valuable strategy to test and revise postu-
lated causality relations in these diseases, which, in turn, should
lead to further improvement of candidate treatment strategies. It
seems reasonable to hope that such an iterative testing process
in improved disease models will provide a rational path to
develop treatments that will at last show efficacy in the clinics.
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